The global nuclear medicine market is projected to grow from USD 16.4 billion in 2024 to USD 69.5 billion by 2034, achieving a CAGR of 15.2%. Factors driving this growth include the rising incidence of cancer and cardiovascular diseases, increased use of targeted radionuclide therapies, advancements in imaging technologies, and a growing elderly population. The market has expanded significantly, from USD 7.8 billion in 2021 to USD 13.6 billion in 2023. Major market players include Cardinal Health, Novartis, and GE Healthcare, which enhance their competitive positions through innovation and R&D investments. Diagnostics lead the market, accounting for 66.1% of revenue in 2024, while therapeutics are expected to grow at a CAGR of 22.1%. Geographically, North America holds the largest share, followed by Europe and the Asia Pacific, which is anticipated to grow the fastest. The increasing need for personalized medicine and technological advancements in imaging systems are expected to further drive market growth and improve patient outcomes.
Thu, 30 Oct 2025 06:31:47 GMT | Global Market Insights Inc.